Prostate and other male cancers:
Indications for: CAMCEVI
Advanced prostate cancer.
Give by SC inj on the upper- or mid-abdominal area. Avoid areas with brawny or fibrous tissue or locations that could be rubbed or compressed. 42mg once every 6months.
Hypersensitivity to GnRH analogues.
May worsen metastatic vertebral lesions and/or urinary tract obstruction; monitor closely during first few weeks. Increased risk of diabetes, MI, sudden cardiac death, stroke. Monitor blood glucose, HbA1c, and for CVD signs/symptoms during therapy. Risk of QT prolongation in those with congenital long QT syndrome, CHF, or frequent electrolyte abnormalities. Correct and monitor electrolyte abnormalities; consider monitoring ECGs. Monitor serum testosterone levels post-inj. Embryo-fetal toxicity. Pregnancy. Nursing mothers: not recommended.
Caution with concomitant drugs known to prolong the QT interval.
Hot flush, hypertension, inj site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, pain in extremity; spinal cord compression, hyperglycemia, convulsions.
Generic Drug Availability:
Kit—1 (w. supplies)